VIGL

Vigil Neuroscience Inc

Add to Watchlist

Advanced Chart

8.050

-0.01(-0.124%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

8.060

Open

8.050

VWAP

8.05

Vol

837.52K

Mkt Cap

375.71M

Low

8.040

Amount

6.74M

EV/EBITDA(TTM)

Total Shares

37.58M

288.60M

EV/OCF(TTM)

P/S(TTM)

Vigil Neuroscience, Inc. is a clinical-stage biotechnology company, which is focused on developing treatments for both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. It is utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities in its efforts to develop precision-based therapies to improve the lives of patients and their families. Its lead clinical candidate, iluzanebart, is a fully human monoclonal antibody agonist targeting the triggering receptor expressed on myeloid cells 2 (TREM2) in people with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease. The Company is also developing VG-3927, a novel small molecule TREM2 agonist, to treat common neurodegenerative diseases associated with microglial dysfunction, with an initial focus on Alzheimer’s disease (AD).

8 Analyst Rating

-0.62% Downside

Wall Street analysts forecast VIGL stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for VIGL is 8.00 USD with a low forecast of 8.00 USD and a high forecast of 8.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

0 Buy

8 Hold

0 Sell

Hold

-0.62% Downside

Current: 8.050

Low

8.00

Averages

8.00

High

8.00

-0.62% Downside

Current: 8.050

Low

8.00

Averages

8.00

High

8.00

H.C. Wainwright

Buy -> Neutral

downgrade

$14 -> $8

2025-05-27

Reason

H.C. Wainwright

Price Target

$14 -> $8

2025-05-27

downgrade

Buy -> Neutral

Reason

H.C. Wainwright downgraded Vigil Neuroscience (VIGL) to Neutral from Buy with a price target of $8, down from $14, after Sanofi (SNY) agreed to acquire Vigil for $470M upfront, with an additional $2 per share contingent on the commercial success of Vigil's Alzheimer's drug, VG-3927, with the deal expected to close in Q3. The firm cites the announced intended acquisition terms for the downgrade.

Stifel

Buy

Hold

downgrade

$11 -> $8

2025-05-27

Reason

Stifel

Price Target

$11 -> $8

2025-05-27

downgrade

Buy

Hold

Reason

Stifel downgraded Vigil Neuroscience (VIGL) to Hold from Buy with a price target of $8, down from $11, following the proposed all-cash transaction by Sanofi (SNY) for $8 per share. Individuals representing 16.2% of Vigil's total common shares outstanding have already signed voting and support agreements in favor of the deal, the analyst tells investors in a research note.

Mizuho

Outperform -> Neutral

downgrade

$13 -> $8

2025-05-23

Reason

Mizuho

Price Target

$13 -> $8

2025-05-23

downgrade

Outperform -> Neutral

Reason

Mizuho downgraded Vigil Neuroscience (VIGL) to Neutral from Outperform with a price target of $8, down from $13, following the company's acquisition by Sanofi (SNY). The firm does not expect another bid to emerge.

Citizens JMP

Outperform -> Market Perform

downgrade

2025-05-22

Reason

Citizens JMP

Price Target

2025-05-22

downgrade

Outperform -> Market Perform

Reason

Citizens JMP downgraded Vigil Neuroscience to Market Perform from Outperform without a price target after the company agreed to be acquired by Sanofi for $ per share upfront. The firm views it as highly likely that the transaction will close as announced.

William Blair

Myles Minter

Outperform -> Market Perform

downgrade

2025-05-22

Reason

William Blair

Myles Minter

Price Target

2025-05-22

downgrade

Outperform -> Market Perform

Reason

William Blair analyst Myles Minter downgraded Vigil Neuroscience to Market Perform from Outperform without a price target after the company agreed to be acquired by Sanofi for $ per share upfront.

Guggenheim

Yatin Suneja

Buy

Neutral

downgrade

2025-05-22

Reason

Guggenheim

Yatin Suneja

Price Target

2025-05-22

downgrade

Buy

Neutral

Reason

Guggenheim analyst Yatin Suneja downgraded Vigil Neuroscience (VIGL) to Neutral from Buy with an $8 price target after the company agreed to be acquired by Sanofi (SNY).

See All Ratings

Valuation Metrics

The current forward P/E ratio for Vigil Neuroscience Inc (VIGL.O) is -4.64, compared to its 5-year average forward P/E of -2.91. For a more detailed relative valuation and DCF analysis to assess Vigil Neuroscience Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-2.91

Current PE

-4.64

Overvalued PE

-1.16

Undervalued PE

-4.66

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-1.17

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.50

Undervalued EV/EBITDA

-2.85

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

0.00

Current PS

0.00

Overvalued PS

0.00

Undervalued PS

0.00